Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis

Abstract

Spanish

Objective:

To examine the clinical aspects of idiopathic pulmonary fibrosis (IPF) and the efficacy and safety of interferon gamma-1b (IFNγ−1b) in its treatment.

Data Sources:

Epidemiologic, preclinical, and clinical studies published in the English language were identified by a MEDLINE search (1966–January 2005) using the search terms idiopathic pulmonary fibrosis, cryptogenic fibrosing alveolitis, and interferon. Additional citations were identified from the reference lists of related publications.

Study Selection and Data Extraction:

Selected preclinical studies describing the pathophysiologic basis for IFNγ−1b therapy and all clinical studies were included. Additional trials describing other treatment modalities and the determinants of response to therapy in patients with IPF were also reviewed.

Data Synthesis:

IFNγ−1b targets the fibrotic rather than inflammatory processes of IPF. The efficacy of IFNγ−1b in patients with IPF is inconsistent with regard to changes in pulmonary function and mortality, although a modest survival benefit was observed in the largest clinical trial. Adverse events related to IFNγ−1b are frequent although transient. Several cases of respiratory failure occurring subsequent to the administration of IFNγ−1b are documented.

CONCLUSIONS:

To date, although trials suggest that earlier-stage IPF may be responsive to IFNγ−1b, study results overall are inconsistent; further investigation is needed.

Keywords

cryptogenic fibrosing alveolitis idiopathic pulmonary fibrosis interferon.

Get full access to this article

View all access options for this article.

References

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med

2000; 161: 646–64.

Panos

Mortenson

Niccoli

King

. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396–404.

Bjoraker

Ryu

Edwin

Myers

Tazelaar

Schroeder

, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199–203.

Schwartz

Helmers

Galvin

Van Fossen

Frees

Dayton

, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 450–4.

King

Tooze

Schwarz

Brown

Cherniack

. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171–81.

Hubbard

Johnston

Britton

. Survival in patients with cryptogenic fibrosing alveolitis: a population based cohort study. Chest 1998; 113: 396–400.

Selman

Thannickal

Pardo

Zisman

Martinez

Lynch

. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004; 64: 405–30.

Selman

King

Pardo

. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136–51.

10.

Prescribing information. Actimmune (interferon gamma-1b). Brisbane, CA: InterMune, March 2004.

11.

Gay

Kazerooni

Toews

Lynch

Gross

Cascade

, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063–72.

12.

King

Schwarz

Brown

Tooze

Colby

Waldron

, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164: 1025–32.

13.

Latsi

du Bois

Nicholson

Colby

Bisirtzoglou

Nikolakopoulou

, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 537.

14.

Hanson

Winterbauer

Kirtland

. Changes in pulmonary function test results after one year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108: 305–10.

15.

Gross

Hunninghake

. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517–25.

16.

Flaherty

Toews

Lynch

Kazerooni

Gross

Strawderman

, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110: 278–82.

17.

Timmer

Karamzadeh

Yung

Kriett

Jamieson

Smith

. Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia. Chest 2002; 122: 779–84.

18.

Erbes

Schaberg

Loddenkemper

. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome? Chest 1997; 111: 51–7.

19.

Flaherty

Thwaite

Kazerooni

Gross

Toews

Colby

, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143–8.

20.

Collard

King

Bartelson

Vourlekis

Schwartz

Brown

. Changes in clinical and physiological variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538–42.

21.

Flaherty

Mumford

Murray

Kazerooni

Gross

Colby

, et al. Prognostic implications of physiologic and radiologic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543–8.

22.

Nicholson

Colby

du Bois

Hansell

. Wells

. The prognostic significance of the histologic pattern of interstitial prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213–7.

23.

Nicholson

Fulford

Colby

du Bois

Hansell

. Wells

. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166: 173–7.

24.

Daniil

Gilchrist

Nicholson

Hansell

Harris

Colby

, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899–905.

25.

Flaherty

Toews

Travis

Colby

Kazerooni

Gross

, et al. Clinical significance of idiopathic interstitial pneumonias. Eur Respir J 2002; 19: 275–83.

26.

King

Safrin

Starko

Brown

Noble

Raghu

, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171–7.

27.

Katzenstein

Myers

. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301–15.

28.

Wallace

WAH

Howie

SEM

. Immunoreactive interleukin 4 and interferon-γ expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999; 187: 475–80.

29.

Douglas

Ryu

Schroeder

. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161: 1172–8.

30.

Raghu

Depaso

Cain

Hammar

Wetzel

Dreis

, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled trial. Am Rev Respir Dis 1991; 144: 291–6.

31.

Zisman

Lynch

Toews

Kazerooni

Flint

Martinez

. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117: 1619–26.

32.

Johnson

Kwan

Snell

NJC

Nunn

Darbyshire

Turner-Warwick

. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280–8.

33.

Selman

Carrillo

Salas

Padilla

Perez-Chavira

Sansores

, et al. Colchicine, d-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled trial. Chest 1998; 114: 507–12.

34.

Douglas

Ryu

Swense

Offord

Schroder

Caron

, et al. Am J Respir Crit Care Med 1998; 158: 220–5.

35.

Ziesche

Hofbauer

Wittmann

Petkov

Block

. A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264–9.

36.

Ziesche

Bradford

Crager

Block

L-H

. Long-term survival in idiopathic pulmonary fibrosis patients treated with interferon gamma-1b. Chest 2002; 122 (suppl): 75S–6S.

37.

Raghu

Brown

Bradford

Starko

Noble

Schwartz

, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125–33.

38.

Raghu

Spada

Otaki

Hayes

. Interferon gamma in the treatment of advanced idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia: prospective, preliminary clinical observations in one center (abstract). Chest 2001; 120 (suppl): 185S.

39.

Antoniou

Polychronopoulos

Dimadi

Rapti

Lambrakis

Latsi

, et al. Comparison of interferon gamma-1b (IFN γ−1b) and colchicine in the treatment of idiopathic pulmonary fibrosis: interim results of a prospective, multicenter randomized study (poster). Presented at: 99th International Conference of the American Thoracic Society, Seattle, May 16–21, 2003.

40.

Bell

Nathan

Shorr

Barnett

Helman

. The effect of interferon alone vs interferon plus corticosteroids in patients with idiopathic pulmonary fibrosis (abstract). Chest 2003; 124: 117S.

41.

Strieter

Starko

Enelow

Noth

Valentine

, Idiopathic Pulmonary Fibrosis Biomarkers Study Group. Effects of interferon-γ 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 170: 133–40.

42.

Kalra

Utz

Ryu

. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc 2003; 78: 1082–7.

43.

Nathan

Barnett

Moran

Kelman

Nicholson

Ahmad

, et al. Interferon gamma-1b as therapy for idiopathic pulmonary fibrosis: an intrapatient analysis. Respiration 2004; 71: 77–82.

44.

Ziesche

Kink

Herold

Podolsky

Block

. Therapy of chronic interstitial lung disease with a combination of interferon-γ and low dose prednisolone (abstract). Chest 1996; 110 (suppl): 25S.

45.

Prasse

Muller

Kurz

Hamm

Virchow

. Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Eur Respir J 2003; 22: 906–11.

46.

Bienkowski

Gotkin

. Control of collagen deposition in mammalian lung. Proc Soc Exp Biol Med 1995; 209: 118–40.

47.

Jiang

Liang

Hodge

Zhu

, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 2004; 114: 291–9.

48.

Elias

Freundlich

Kern

Rosenbloom

. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1990; 97: 1439–45.

49.

Narayanan

Whithey

Souza

Raghu

. Effect of γ−interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992; 101: 1326–31.

50.

Clark

Dedon

Wayner

Carter

. Effects of interferon-γ on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J Clin Invest 1989; 83: 1505–11.

51.

Okada

Sugie

Aisaka

. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res 1993; 12: 87–91.

52.

Sempowski

Derdak

Phipps

. Interleukin-4 and interferon-γ discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol 1996; 167: 290–6.

53.

Gurujeyalakshmi

Giri

. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TFG-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791–808.

54.

Venkatesan

Roughley

Ludwig

. Proteoglycan expression in lung fibroblasts: role of transforming growth factor beta-1 and interferon-gamma. Am J Physiol Lung Cell Mol Physiol 2002; 283: L806–14.

55.

Data on file. InterMune, Brisbane, CA, 2004.

56.

Prior

Haslam

. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992; 88: 280–7.

57.

Wen

Liu

Kobayashi

Abe

Fang

Kohyama

, et al. Interferon-γ inhibits transforming growth factor-β production in human airway epithelial cells by targeting smads. Am J Respir Cell Mol Biol 2004; 30: 816–22.

58.

Honore

Nunes

Groussard

Kambouchner

Chambellan

Aubier

, et al. Acute respiratory failure after interferon gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003; 167: 953–7.

59.

Crestani

Valeyre

. Acute respiratory failure after interferon-γ therapy in IPF. Am J Respir Crit Care Med 2004; 169: 543–4.

60.

2004 Drug topics red book. Montvale, NJ: Thompson PDR, 2004.